Detalles de la búsqueda
1.
Meaningful Symptomatic Change in Patients With Myelofibrosis From the SIMPLIFY Studies.
Value Health
; 27(5): 607-613, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38311180
2.
Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial.
Haematologica
; 108(10): 2730-2742, 2023 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37165840
3.
VEXAS syndrome: A review of bone marrow aspirate and biopsies reporting myeloid and erythroid precursor vacuolation.
Eur J Haematol
; 110(6): 633-638, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-36788756
4.
Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low-, intermediate-1-, intermediate-2-, and high-risk myelofibrosis in JUMP, a Phase 3b, expanded-access study.
Hematol Oncol
; 39(4): 558-566, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34224180
5.
Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.
Br J Haematol
; 189(5): 888-903, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32017044
6.
Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis.
Haematologica
; 102(2): 327-335, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27789678
7.
The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey.
Ann Hematol
; 96(10): 1653-1665, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-28780729
8.
Perioperative management of myeloproliferative neoplasms: A pan-Canadian physician survey and international expert opinion.
Am J Hematol
; 97(12): E466-E469, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36151067
9.
Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial.
Haematologica
; 101(9): 1065-73, 2016 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-27247324
10.
Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: primary analysis of FREEDOM trial.
Leuk Lymphoma
; : 1-11, 2024 Jun 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38838026
11.
Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study.
Bone Marrow Transplant
; 59(2): 196-202, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37938736
12.
Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies.
Cancer Med
; 12(9): 10612-10624, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37021939
13.
Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study.
Hemasphere
; 7(11): e966, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37901848
14.
The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies.
Haematologica
; 101(12): e482-e484, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27587385
15.
Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study.
Leuk Lymphoma
; 62(4): 918-926, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33210570
16.
Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study.
Leukemia
; 35(12): 3455-3465, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34017073
17.
Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy.
Hematol Oncol
; 28(1): 40-8, 2010 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-19557769
18.
No Differences in Outcomes Between JAK2 V617F-Positive Patients with Variant Allele Fraction < 2% Versus 2-10%: A 6-Year Province-wide Retrospective Analysis.
Clin Lymphoma Myeloma Leuk
; 20(9): e569-e578, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32439277
19.
Patterns of Ruxolitinib Therapy Failure and Its Management in Myelofibrosis: Perspectives of the Canadian Myeloproliferative Neoplasm Group.
JCO Oncol Pract
; 16(7): 351-359, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32134707
20.
Safety and efficacy findings from the open-label, multicenter, phase 3b, expanded treatment protocol study of ruxolitinib for treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea and for whom no alternative treatments are available.
Leuk Lymphoma
; 60(14): 3493-3502, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31359808